In addition, MAPT mutation carriers are known for their rapid cognitive decline once they become symptomatic,2 probably causing lower performance on neuropsychological tests compared to patients with a GRN or C9orf72 mutation in their early symptomatic stages. This evidence concerns the gene GRN and Mental deterioration.